THE STATE OF CURRENT MANAGEMENT OF THE HEIGHTENED RISK FOR ATHEROSCLEROTIC CARDIOVASCULAR EVENTS IN AN ESTABLISHED COHORT OF PATIENTS WITH LUPUS ERYTHEMATOSUS

Megan Zhao, BA[1,2], Rui Feng, PhD[3], Victoria P. Werth, MD[1,2*], Kevin Jon Williams, MD[4*]

[1]Corporal Michael J. Crescenz Veterans' Administration Medical Center, Philadelphia, PA, USA
[2]Department of Dermatology, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
[3]Department of Biostatistics, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
[4]Department of Cardiovascular Sciences, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
*Co-senior authors

Abstract

Aims: Patients with lupus erythematosus (LE) are at a heightened risk for clinical events, chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). To address this problem, we recently proposed new guidelines for categorization of levels of risk for future ASCVD events specifically in LE patients, with corresponding recommendations for management.[1]

Methods and Results: We included all participants in our established UPenn Longitudinal Lupus Cohort of patients with cutaneous LE, without or with concurrent systemic LE (n=370, LE-ASCVD Study Cohort, years 2007 to 2021). Of our LE-ASCVD Study Cohort, 336/370 (90.8%) had a designated primary care physician. By the new guidelines, the most recent plasma low-density lipoprotein cholesterol (LDLc) levels were above goal for 252/370 (68.1%) of the LE-ASCVD Study Cohort. Of the Study Cohort, 266 (71.9%) had hypertension, which was under- or un-treated in 198/266 (74.4%). Of current smokers, 51/63 (81.0%) have no chart documentation of smoking cessation counseling or clinic referral. Diabetes was generally well-managed, and hypertriglyceridemia was uncommon. Of the LE-ASCVD Study Cohort, 254 patients qualified for two widely used online calculators that estimate the risk of an ASCVD

event in the next 10 years ("10-year ASCVD event risk"): the ACC-ASCVD Risk Estimator Plus and QRisk3. We also stratified these 254 patients into the categories of ASCVD event risk defined by Keyes et al. Surprisingly, these three methods for estimating ASCVD event risk showed clinically meaningful agreement for only 100/254 (39.4%), i.e., discordance for over 60% of LE patients that could affect their clinical management. The actual documented rate of ASCVD events for patients in the first 10 years after enrollment into the Cohort was 22.3% (95% CI 16.9%, 27.4%), indicating a high-risk population despite a preponderance of women and a median age of only 47 years at enrollment.

Conclusion: We conclude that cutaneous LE patients are under-treated compared with the new guidelines and, accordingly, these patients experience a substantial burden of major adverse ASCVD events. Moreover, it is unclear how to accurately assess future ASCVD event risk in cutaneous LE patients – except that it is high – and this uncertainty may complicate clinical management. Efforts are underway to improve ASCVD event risk estimation and guideline implementation in lupus patients.

Introduction

Patients with lupus erythematosus (LE) suffer from a heightened risk of clinical events, chiefly heart attacks and strokes, caused by atherosclerotic cardiovascular disease (ASCVD). Several clinical features of LE contribute to the problem.[1] First, patients with LE exhibit an increased prevalence of conventional risk factors for ASCVD events, particularly dyslipoproteinemia and hypertension, and glucocorticoid use often exacerbates additional conditions related to cardiovascular risk, such as obesity, the metabolic syndrome, so-called "prediabetes" (defined as dysglycemia to an extent that indicates a high risk of developing diabetes), and type 2 diabetes mellitus.[1, 2] Moreover, patients with cutaneous LE (CLE) smoke at

54 higher rates than in the general population.[3-5] Second, numerous studies using arterial
55 ultrasonography, coronary CT angiography, and other methods have shown that LE patients
56 carry an increased burden of atherosclerotic plaques compared with the general population.[1, 6-9]
57 Third, the increased rate of ASCVD events amongst LE patients persists even after adjustment
58 for age and sex and, more strikingly, even after adjustment for other conventional risk factors for
59 ASCVD events.[1, 10, 11] We have suggested that autoimmune processes specific to LE may
60 exacerbate specific, known pathogenic steps in atherosclerosis.[1]

61 Despite their high plaque burden and heightened risk for ASCVD events, however, LE
62 patients remain undertreated for the causative agents of ASCVD, meaning low-density
63 lipoprotein (LDL) and other cholesterol-rich apolipoprotein-B (apoB)-containing lipoproteins,[12,
64 13] and key exacerbators of ASCVD, such as hypertension, smoking, and hyperglycemia.[1, 14-17]
65 As part of our efforts to address this problem, we recently proposed a system for assessing CLE
66 and systemic LE (SLE) patients using four defined categories of ASCVD event risk, with
67 corresponding guidance for clinical management of LE patients in each ASCVD event risk
68 category using lifestyle modifications and modern medications.[1]

69 In the current work, we performed a single-center study of all 370 patients with CLE,
70 without or with concurrent SLE, within our established longitudinal cohort at the University of
71 Pennsylvania Health System (UPHS) for whom we have full access to their medical records.[18-23]
72 Our goal was to assess the state of current management of ASCVD event risk through
73 conventional therapeutic targets, chiefly hyperlipidemia, hypertension, smoking, prediabetes, and
74 diabetes mellitus, in the light of the new recommendations.[1] We also studied two earlier and still
75 widely used online tools for estimating the risk of an ASCVD event in the next 10 years ("10-

76 year ASCVD event risk"): the American College of Cardiology (ACC) ASCVD Risk Estimator

77 Plus[24, 25] and the QRisk3 calculator.[26-28]

Methods

The LE-ASCVD Study Cohort

We previously reported the UPenn Longitudinal Lupus Cohort, which is our established cohort of patients receiving care at UPHS whom we have been recruiting from our specialty Dermatology clinic since 2007 based on a diagnosis of CLE, without or with concurrent SLE.[18-23] The UPHS Institutional Review Board approved patient recruitment and then collection and analyses of data, and we obtained written informed consent from each participant.

For the current study, we required full access to longitudinal and recent medical records. Thus, we included only active UPHS patients and patients whose records from outside hospitals were either linked or faxed into the UPHS electronic medical record ("LE-ASCVD Study Cohort"). Our database consisted of clinical information for these patients, including ASCVD events and parameters relevant to management of future ASCVD event risk, that we entered into the University's secure RedCap system (Research Electronic Data Capture, Vanderbilt University, Nashville, TN, USA) to ensure compliance with confidentiality requirements of the Health Insurance Portability and Accountability Act of 1996 (HIPAA).

Demographic and clinical data collected for the RedCap database

Demographic and clinical data collected for the LE-ASCVD Study Cohort included sex, race/ethnicity, age at enrollment, age as of 2021, time since enrollment in our cohort, time since CLE diagnosis, whether there was also a diagnosis of SLE, and, if so, time since SLE diagnosis. When simultaneous heights and weights were available, we calculated body mass indices (BMIs), to stratify the patients into categories of underweight (commonly defined as <18.5 kg/m^2 but alternatively as <20.0 kg/m^2 based on mortality data[29]), normal weight (commonly defined

101 as 18.5 to 24.9 kg/m^2 but also as 20.0 to 24.9 kg/m^2),[29] overweight (25.0 to 29.9 kg/m^2), or
102 obese (≥30.0 kg/m^2). Amongst the LE-ASCVD Study Cohort, a diagnosis of depression in the
103 electronic medical record, history of lupus nephritis, history of chronic kidney disease (CKD)
104 stage 3 or higher, and smoking status (never, former, or current) from chart abstraction were also
105 entered into our RedCap database.

106 In our RedCap database, we also included whether there was a listed primary care
107 provider (PCP), and the date of the last PCP visit was noted. All specialties caring for the
108 patients within the past 20 years, if available, were compiled.

109 Orders and results for lipid/lipoprotein panels and glycated hemoglobin (HbA_{1c}) levels
110 were extracted from the electronic medical records, including dates and the specialty of the
111 ordering physician. Lipid/lipoprotein panels typically did not include a full set of conventional
112 values, meaning plasma concentrations of total cholesterol (TC), LDL cholesterol (LDLc),
113 triglycerides (TG), high-density lipoprotein cholesterol (HDLc), apolipoprotein-B (apoB), and a
114 one-time assay for lipoprotein(a) [Lp(a)];[1, 30-32] thus, our tabulations often show an n less than
115 the full LE-ASCVD Study Cohort. Non-HDLc, a convenient parameter that captures the
116 cholesterol carried by LDL and all other atherogenic apoB-lipoproteins, was calculated as TC
117 minus HDLc. All blood pressure values in each patient's chart were entered into our RedCap
118 database, to allow us to assess recent blood pressure management and to calculate blood pressure
119 variability, a parameter included in the QRisk3 calculator. Hypertension was defined as a
120 systolic blood pressure ≥130, a diastolic pressure ≥80 mm Hg, and/or on anti-hypertensive
121 medication, following the recently updated joint guidelines from the ACC and the American
122 Heart Association (AHA).[17, 33] We averaged blood pressure readings from the most recent year
123 of follow-up.

124 Following criteria from the American Diabetes Association (ADA), HbA_{1c} values of 5.7-
125 6.4% indicate prediabetes, and HbA_{1c} ≥6.5% is diagnostic for diabetes mellitus.[34] Accordingly,
126 prediabetes was defined here as chart-diagnosed or the most recent HbA_{1c} was 5.7-6.4%, without
127 a diagnosis of overt diabetes on the chart. Diabetes was defined as chart-diagnosed or the most
128 recent HbA_{1c} was ≥6.5%. The most recent HbA_{1c} value for some patients with a diagnosis of
129 diabetes mellitus was below 6.5%; we still classified them under diabetes unless a clinician had
130 marked the diagnosis on the chart as resolved or in remission. For patients with diabetes, HbA_{1c}
131 values ≤7% indicate that the condition is well-controlled.[34-38]
132 Documentation in the electronic charts of counseling on lifestyle changes, specifically
133 diet, exercise, weight loss, and smoking cessation, was noted along with dates of counseling.
134 Referrals to dieticians, weight-loss programs, and smoking cessation clinics were also included.
135 From physicians' and other providers' notes and the medication lists in the charts, we extracted
136 prescriptions for medications for lipid-lowering, hypertension, and glycemic control, as well as
137 the dates of these prescriptions.
138 All previously documented or newly incident major adverse atherosclerotic
139 cardiovascular events (MAACE) were noted along with the event date and were defined as
140 atherosclerotic myocardial infarction (MI), atherosclerotic ischemic heart disease other than MI
141 such as angina and coronary revascularization, atherosclerotic (non-embolic) ischemic stroke or
142 transient cerebrovascular ischemic attack, newly diagnosed symptomatic peripheral arterial
143 disease (PVD), or hospitalization for chest pain, shortness of breath, or palpitations with
144 suspicion of ischemic origin. Major adverse cardiovascular events (MACE) that were clearly not
145 atherosclerotic were excluded, such as coronary vasospasm without documentation of nearby
146 plaque, embolic stroke unrelated to atherosclerosis, and heart failure from non-ischemic causes

147 (chronic hypertension, diabetes mellitus, non-ischemic valvular disorders, post-myocarditis, and
148 congenital or genetic defects).
149
150 *Three systems to estimate the risk of a future ASCVD event for individual patients within the LE-*
151 *ASCVD Study Cohort*
152 Based on these clinical data, including absence or presence of clinically evident ASCVD
153 and major conventional risk factors for ASCVD events, we classified patients from the LE-
154 ASCVD Cohort into the four defined categories of ASCVD event risk from our recently
155 proposed guidelines for ASCVD event risk management for LE patients[1] – namely, High Risk,
156 Very High Risk, Extreme Risk, and Recent Recurrent ASCVD Events. Next, we compared
157 current clinical care with the new therapeutic goals for each of these categories of ASCVD event
158 risk for LE patients.[1]
159 In addition, we evaluated patients in the LE-ASCVD Cohort with two widely used online
160 calculators that estimate 10-year ASCVD event risk for individuals from the general population,
161 i.e., not specifically designed for CLE patients. Use of these online calculators was limited to
162 patients with sufficient data in the electronic chart and no clinically evident ASCVD (primary
163 prevention); the calculators are not designed to estimate future ASCVD event risk in patients
164 who have already had an atherosclerotic cardiovascular event (secondary prevention). One of
165 the online calculators that we used was the ACC ASCVD Risk Estimator Plus, which may be the
166 best known but does not take a diagnosis of LE into consideration.[24, 25] Moreover, it calculates
167 10-year ASCVD event risk only for patients aged 40-79 years. To allow calculations as broadly
168 as possible, patients in our LE-ASCVD Cohort below age 40 years without clinically evident
169 ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus were scaled

170 up to 40, and patients above age 79 years without clinically evident ASCVD were scaled down
171 to 79. For simplicity, we did not include multipliers of this estimation of 10-year ASCVD event
172 risk, although some authors have advocated such multipliers for LE patients.[1, 39] There were just
173 two patients with TC >320 mg/dL, the highest value allowed by the ACC ASCVD Risk
174 Estimator Plus, so we scaled those values to 320. We stratified LE patients by their estimated 10-
175 year ASCVD event risks from the ACC Risk Estimator Plus, following the cutoffs of Arnett et
176 al. in the ACC/AHA guidelines for primary prevention in the general population[25] – namely,
177 0.0-4.9% 10-year ASCVD event risk (low), 5.0-7.4% (borderline), 7.5-19.9% (intermediate), and
178 ≥20% (high).
179 The other online calculator that we used to estimate 10-year ASCVD event risk was
180 QRisk3, which includes SLE status and use of orally administered steroids, but not CLE status,
181 and requires that patients not be prescribed statins at baseline.[26, 27] QRisk3 can be used for
182 patients aged 25-84 years, so we scaled up three patients to an age of 25 and scaled down four
183 patients to an age of 84. The QRisk3, which is based in the United Kingdom, draws on data for
184 specific racial/ethnic groups there that do not include large numbers of African Americans or
185 Hispanics, and so patients from our LE-ASCVD Cohort in those demographics had to be
186 classified under the QRisk3 category of "Other ethnic group". The ACC ASCVD Risk
187 Estimator Plus, which is based in the USA and therefore more aligned with the population of our
188 catchment area, does not have this limitation. Online estimates were performed by one author
189 (MZ), and divergent estimates of 10-year event risk between the two online calculators were
190 spot-checked by another author (KJW).
191
192 *Statistical analyses*

193 Categorical parameters are given as n (%). Continuous variables are given as mean±SD,
194 if normally distributed, or as median (interquartile range, IQR), if non-normally distributed.
195 We used several approaches to compare the three systems to estimate the risk of a future
196 ASCVD event in this Cohort – namely, the categories of ASCVD event risk for LE patients from
197 Keyes et al.[1] and the two widely used online calculators that estimate 10-year ASCVD event
198 risk in primary prevention.[24, 28] To assess the correlation between the numerical estimates of 10-
199 year ASCVD event risk from the QRisk3 versus the ACC Risk Estimator Plus for all patients in
200 the LE-ASCVD Study Cohort for whom we could use both, we calculated a Pearson's
201 correlation coefficient (r) and fit a linear regression.
202 To compare the two online calculators with the newly proposed categories of ASCVD
203 event risk for LE patients from Keyes et al., we used the key cutoff of 7.5% estimated 10-year
204 ASCVD event risk from Arnett et al.'s ACC/AHA guidelines for primary prevention in the
205 general population.[25] In those guidelines, estimates of 10-year ASCVD event risk ≥7.5% come
206 with substantially more aggressive recommendations for management compared with the
207 recommendations for patients with estimates of 10-year ASCVD event risk <7.5%.[25]
208 Thus, we defined clinically meaningful agreement amongst the three methods as
209 classification of an LE patient into the "High Risk" or "Very High Risk" categories of primary
210 prevention from Keyes et al., along with estimates of 10-year ASCVD event risk ≥7.5% from
211 both of the online calculators. Clinically significant discordance between the two online
212 calculators meant estimates of 10-year ASCVD event risk for an LE patient that were <7.5%
213 from one calculator but ≥7.5% from the other. Discordance between the categories of Keyes et
214 al. versus both of the online risk estimators occurred in patients who were at High or Very High

215 Risk according to Keyes et al., yet both online calculators gave estimates of 10-year ASCVD
216 event risk <7.5%.
217 Documented major adverse atherosclerotic cardiovascular events (MAACE) were
218 tabulated for the period before enrollment into the Cohort and then for the entire period of study
219 after enrollment. Event-free survival rates since enrollment in the LE-ASCVD Study Cohort
220 were computed according to Kaplan & Meier, along with 95% confidence intervals.[40, 41] The
221 actual documented rate of ASCVD events for patients in the first 10 years after enrollment into
222 the LE-ASCVD Study Cohort was calculated as one minus the event-free survival rate at the 10-
223 year time point of the Kaplan-Meier survival curve.
224 This study followed the principles outlined in the Declaration of Helsinki.

225 **Results**

226 The UPenn Longitudinal Lupus Cohort currently consists of 529 CLE patients.[21-23] Upon
227 review, we found that 370 of them have electronic medical records that are fully accessible
228 within UPHS and therefore could be included in our LE-ASCVD Study Cohort.

229 Table 1 shows demographics and other characteristics of the LE-ASCVD Study Cohort.
230 Consistent with our previous reports,[1, 21, 23] the LE-ASCVD Study Cohort was predominantly
231 female (82.4%), with nearly nine out of 10 identifying as White (51.4%) or Black (38.1%),
232 consistent with the UPHS catchment area. Average age was 47.1±14.9 years at enrollment and
233 54.8±15.9 years at the end of the data collection period (Table 1). Average length of time since
234 enrollment into the UPenn Longitudinal Lupus Cohort was 7.7±4.5 years.

235 As of their most recent medical encounter, 22.2% of the patients in our LE-ASCVD
236 Study Cohort had clinically evident ASCVD, meaning a diagnosis of MAACE as defined in the
237 Methods, which classifies these individuals as candidates for secondary prevention (n=82/370;
238 Extreme Risk in Table 1 and in Figure 1A; no patient qualified for the highest-risk category from
239 Keyes et al. of Recent Recurrent ASCVD Events). Just over half of the LE-ASCVD Study
240 Cohort had concurrent SLE (51.4%), with 11.4% having a history of lupus nephritis, and 10.0%
241 having a history of stage 3 or 4 CKD. Median times since diagnosis of CLE or concurrent SLE
242 were over a decade (Supplementary Table S1). Almost three-quarters of the patients in the LE-
243 ASCVD Study Cohort (71.9%) had hypertension, 29.5% were former smokers, and 17.0% are
244 current smokers (Table 1). Of the subgroup with at least one set of simultaneous height and
245 weight measurements, approximately one-third were underweight or normal weight (n=125/346,
246 36.2%), one-third overweight (30.3%), and one-third obese (33.5%; Table 1 and Supplementary
247 Table S1). Prediabetes was present in 18.1%, and diabetes in 10.5%, of the LE-ASCVD Study

248 Cohort (Table 1). A diagnosis of depression was common (37.6%; Supplementary Table S1), as
249 previously reported for CLE.[42]
250 Regarding management, nearly all the patients in the LE-ASCVD Study Cohort had a
251 primary-care physician listed in the electronic medical record (90.8%; Table 1). Time elapsed
252 since the last visit with a primary-care physician was 10 months (IQR 4.0-31; Supplementary
253 Table S1). Number of physician providers, excluding trainees, was 5.8±2.8 per patient
254 (mean±SD; Supplementary Table S1). Most patients in the Study Cohort had seen a
255 rheumatologist (203/307, 54.9%), and under half had seen a cardiologist (40.8%), nephrologist
256 (15.4%), or endocrinologist (8.0%; Supplementary Table S1).
257
258 *Assessments and management of lipid/lipoprotein levels as targets to lower ASCVD event risk*
259 The vast majority (n=325/370, 87.8%) of patients in the LE-ASCVD Study Cohort had
260 plasma lipid/lipoprotein levels checked at least once, with a median elapsed time of 35 months
261 (IQR 14-83) since the most recent panel, i.e., almost three years (Supplementary Table S1). We
262 found that PCPs checked just over 60% of the most recent lipid/lipoprotein values, and non-
263 PCPs checked the rest. Of the non-PCPs, rheumatologists checked lipid/lipoprotein values in
264 more patients than did other subspecialists (Supplementary Table S1).
265 Using our recently proposed guidelines that we tailored specifically for lupus patients,[1]
266 almost one-quarter of LE patients classified at High Risk for an ASCVD event had plasma LDLc
267 concentrations that were above the newly recommended ranges (n=11/52, 21.2%; red in the
268 leftmost column of Figure 1A). More strikingly, over three-quarters of LE patients classified at
269 either Very High Risk (179/236, 75.8%) or Extreme Risk (62/82, 75.6%) for an ASCVD event
270 also had plasma LDLc concentrations above the newly recommended ranges (red in the middle

271 two columns of Figure 1A). For the 252 LE patients whose most recent LDLc value was above-
272 goal, the time elapsed since that above-goal LDLc was 47 months (IQR 24-97), i.e., almost four
273 years (Supplementary Table S1). Data for non-HDLc levels were similar: 13.5% (7/52), 66.5%
274 (157/236), and 72.0% (59/82) of our LE patients in these three categories of ASCVD event risk
275 had values above the newly recommended ranges (Supplementary Figure S1A).

276 Regarding lipid/lipoprotein management in primary prevention, 90.9% (n=10/11) of High
277 Risk patients with out-of-range LDLc levels were not on any LDL-lowering medications
278 recorded in their charts, and 70.4% (n=126/179) of Very High Risk patients with out-of-range
279 LDLc levels were not on LDL-lowering medications (Figure 1B). Again, data for non-HDLc
280 levels were similar: 85.7% (6/7), and 72.6% (114/157) of LE patients in these two categories of
281 ASCVD event risk with out-of-range non-HDLc levels were not on any LDL-lowering
282 medications (Supplementary Figure S1B). Thus, over two-thirds of LE patients classified at High
283 or Very High ASCVD event risk with out-of-range LDLc or non-HDLc values according to the
284 newly published guidelines were on no LDL-lowering medications.

285 Of the 82 LE patients classified at Extreme ASCVD event risk (secondary prevention),
286 only about one in ten achieved plasma concentrations of LDLc (8/82, 9.8%) or non-HDLc
287 (11/82, 13.4%) within the new goals. Nearly half were under-treated by the new guidelines,
288 meaning on LDL-lowering medications but still with out-of-range values for LDLc (37/82,
289 45.1%) or non-HDLc (34/82, 41.5%). About 30% were untreated, meaning out-of-range values
290 for LDLc (25/82, 30.5%) or non-HDLc (also 25/82, 30.5%) yet on no LDL-lowering
291 medications. The remainder of the LE patients classified at Extreme ASCVD event risk had no
292 LDLc (12/82, 14.6%) or HDLc (also 12/82, 14.6%) values available from their charts despite

293 documentation of clinically evident ASCVD, the key requirement for this risk category[1] (Figure
294 1B, Supplementary Figure S1B).

295 We used the ACC ASCVD Risk Estimator Plus to estimate the risk of an ASCVD event
296 in the next 10 years ("10-year ASCVD event risk") for all patients in the LE-ASCVD Study
297 Cohort meeting the criteria of no clinically evident ASCVD (n=288/370, 77.8% of the Study
298 Cohort; Figure 1A, Table 1), with sufficient available clinical data to allow use of this online risk
299 estimator (n=254), and ages 40-79 years (n=194). By performing age-scaling as described in the
300 Methods, we included an additional 47 patients below the age of 40 years (12.7% of the LE-
301 ASCVD Study Cohort) and 13 patients above 79 years (3.5% of the Study Cohort) without
302 clinically evident ASCVD and with sufficient data for this online ASCVD event risk estimator,
303 to analyze the entire subset of 254 patients just mentioned, i.e., nearly 90% of the LE-ASCVD
304 Study Cohort who had no clinically evident ASCVD (254/288, 88.2%).

305 Figure 1C displays data for these 254 patients stratified by estimates of their 10-year
306 ASCVD event risk from the ACC ASCVD Risk Estimator Plus, following the cutoffs of Arnett
307 et al. for primary prevention in the general population.[25] Of the patients with an estimated 10-
308 year ASCVD event risk of 7.5% to 19.9% from the ACC ASCVD Risk Estimator Plus, over half
309 were not on any LDL-lowering medication (n=43 out of 73, 58.9%; Figure 1C). Of patients with
310 an estimated 10-year ASCVD event risk ≥20%, 42.9% (n=12/28) were not on an LDL-lowering
311 medication recorded in the chart. Supplementary Figure S1C shows nearly identical results from
312 the original subset of 194 LE patients with no clinically evident ASCVD, sufficient data for this
313 online risk estimator, and aged 40-79 years with no age-scaling.

314 Of the LE patients who already have clinically evident ASCVD and are therefore
315 candidates for secondary prevention of ASCVD events, 41.5% (n=34/82) were not on any LDL-

316 lowering medication; this figure comprises Extreme Risk patients on no LDL-lowering
317 medication who have either (i) no LDLc value available (7 out of 12 from Figure 1A), (ii) the
318 most recent LDLc value within goal (2 out of 8 from Figure 1A), or (iii) the most recent LDLc
319 value above goal (25 from Figure 1B).

320 Figure 1D shows data for patients in the LE-ASCVD Study Cohort stratified by their
321 most recent plasma LDLc concentrations, and then within each LDLc concentration range, we
322 indicate treatment, or not, with an LDL-lowering medication. In each LDLc concentration
323 range, except for the lowest (<70 mg/dl) and the highest (≥190 mg/dl), over 60% of our LE
324 patients were on no LDL-lowering medications. There was no LDLc value available in the chart
325 for 45 patients (12.2% of the entire LE-ASCVD Study Cohort), nearly all of whom were on no
326 LDL-lowering medications (n=39/45, 86.7%). Supplementary Figure 1D shows data from
327 stratifying LE patients by their most recent plasma non-HDLc concentrations. Similar to our
328 findings with LDLc, in each concentration range of non-HDLc, except for the lowest (<80
329 mg/dl) and the highest (≥220 mg/dl), over 60% of LE patients were on no LDL-lowering
330 medications (Supplementary Figure S1D).

331

332 *Assessments and management of hypertension*

333 As noted above, almost three-quarters of the LE-ASCVD Study Cohort had hypertension
334 (266/370, 71.9%; Table 1). Of these 266 hypertensive lupus patients, approximately one-fourth
335 were well-managed, meaning normotensive on anti-hypertensive medications (68/266, 25.6%;
336 green in the leftmost column of Figure 2A); almost one half were under-treated, meaning on anti-
337 hypertensive medications but still hypertensive (122/266, 45.9%; green in the middle column of
338 Figure 2A); and almost one third were untreated, meaning hypertensive yet on no anti-

339 hypertensive medication (76/266, 28.6%; red in the middle column of Figure 2A). These data
340 indicate that hypertension is a common but undermanaged problem in lupus patients, consistent
341 with recently published literature using these blood pressure cut-offs.[17]
342
343 *Smoking status and management*
344 Figure 2B indicates the prevalence and management of tobacco smoking in the LE-
345 ASCVD Study Cohort. Of the former smokers in our cohort, the overwhelming majority quit
346 smoking without any documentation in the chart of smoking cessation counseling or referral to a
347 specialized smoking cessation clinic (n=92/109, 84.4%). Similarly, the overwhelming majority
348 of current smokers have no documentation in their charts of smoking cessation counseling or
349 clinic referral (n=51/63, 81.0%).
350
351 *Assessments and management of HbA_{1c} and plasma triglyceride levels*
352 The majority (n=208/370, 56.2%) of patients in the LE-ASCVD Study Cohort had their
353 HbA_{1c} levels checked at least once, with a median time elapsed time of 36 months (IQR 11-68)
354 since the last assay, i.e., three years (Supplementary Table S1). As with lipid/lipoprotein values,
355 PCPs checked just over 60% of the most recent HbA_{1c} levels, and non-PCPs checked the rest. Of
356 the non-PCPs, rheumatologists checked HbA_{1c} levels in more patients than did other
357 subspecialists (Supplementary Table S1).
358 Figure 2C shows assessment, or not, of HbA_{1c} values in the LE-ASCVD Study Cohort
359 after stratification by obesity and/or current or previous glucocorticoid use, two common factors
360 in lupus patients that impair glycemic control. Of note, 51.0% (51 out of 100) of non-obese LE
361 patients on glucocorticoids, 30.6% (22/72) of obese LE patients not on glucocorticoids, and

362 38.6% (17/44) of obese LE patients on glucocorticoids had no HbA_{1c} value in their electronic
363 charts. In those three groups, 17.0% (n=17/100), 47.2% (n=34/72), and 31.8% (n=14/44) of the
364 patients had documented prediabetes or diabetes (blue and yellow in Figure 2C), suggesting that
365 obesity is a bigger driver of dysglycemia in the LE-ASCVD Study Cohort than are GCs. For
366 comparison, the figure for non-obese LE patients not on glucocorticoids is 23.4% (n=36/154;
367 leftmost column in Figure 2C). For patients whose most recent HbA_{1c} value was indicative of
368 prediabetes or diabetes, meaning ≥5.7%, the time elapsed since that abnormal value was 48
369 months (IQR 24-80), i.e., four years (Supplementary Table S1).
370 For LE patients with a diagnosis of prediabetes, almost half (33/67, 49.3%) did not have
371 documentation of lifestyle modification counseling or an active prescription for metformin
372 prescription in their charts (Figure 2D). For LE patients with diabetes, however, over three-
373 quarters were well-managed (n=30/39, 76.9%), and only 10.3% (4/39) had a most recent HbA_{1c}
374 >7% (Figure 2D).
375 Regarding triglyceride management, only 10.0% (10/100) of non-obese LE patients on
376 glucocorticoids, 5.6% (4/72) of obese LE patients not on glucocorticoids, and 9.1% (4/44) of
377 obese LE patients on glucocorticoids had no plasma triglyceride value in their electronic charts
378 (Figure 2E). Of all patients in the LE-ASCVD Study Cohort with available triglyceride values
379 (n=331 out of 370, 89.5%), only 0.6% (2/331) had very high levels (≥500 mg/dl) and only 6.0%
380 (20/331) had high levels (200-499 mg/dl; Figure 2E). These data indicate that
381 hypertriglyceridemia was not a common problem in our LE-ASCVD Study Cohort even amongst
382 patients with obesity and/or glucocorticoid therapy.
383

384 *Comparisons of three different systems for estimating the risk of future ASCVD events in LE*
385 *patients*

386 We examined three systems for estimating the risk of future ASCVD events in LE
387 patients – namely, the newly proposed risk categories of Keyes et al, which include both primary
388 and secondary prevention,[1] and the two widely used online risk calculators, cited above, that
389 estimate 10-year ASCVD event risk and are limited to primary prevention. To compare these
390 systems in our LE-ASCVD Study Cohort, we focused on the subset of patients for whom both
391 the QRisk3 and the ACC ASCVD Risk Estimator Plus could be used, meaning sufficient data in
392 the electronic chart and no clinically evident ASCVD (n=254 out of 370 when including age
393 scaling, i.e., the same number classified by the ACC ASCVD Risk Estimator Plus in Figure 1C).
394 We separated these 254 patients into "High Risk" (n=41 out of 254; blue dots in Figure 3A,B)
395 and "Very High Risk" (n=213/254; yellow dots in Figure 3A,C) following the categories of
396 Keyes et al.[1] None of these 254 LE patients met criteria for the categories of "Extreme Risk" or
397 "Recent Recurrent ASCVD Events" from Keyes et al., because both of those categories require
398 clinically evident ASCVD, hence secondary prevention and ineligible for the QRisk3 or ACC
399 ASCVD risk estimators.

400 Figure 3A shows estimates of each of these patient's 10-year ASCVD event risk from the
401 QRisk3 and from the ACC calculator. Figure 3B shows both estimates of 10-year ASCVD event
402 risk for only the LE patients who were stratified into the "High Risk" category of Keyes et al.,
403 with the axes expanded for ease of viewing the data. Figure 3C shows both 10-year ASCVD
404 event risk estimates for only the LE patients stratified into the "Very High Risk" category of
405 Keyes et al. Figure 3C allows an unobstructed view of the data for these Very High Risk

406 patients, indicating that many of them had remarkably low estimates of 10-year ASCVD event
407 risk from one or both of the online calculators, a point we return to in Figure 3D.
408 To directly compare the numerical estimates of 10-year ASCVD event risk from the
409 QRisk3 and the ACC ASCVD Risk Estimator Plus in our LE-ASCVD Study Cohort, we
410 performed Pearson's correlation with age scaling (Figure 3A, n=254 patients) and without age
411 scaling (Supplementary Figure S2A, n=194 patients, i.e., the same number classified by the ACC
412 ASCVD Risk Estimator Plus in Supplementary Figure S1C). Correlations were highly
413 statistically significant, with p-values of 1.78×10^{-41} and 1.40×10^{-27}, respectively. Nevertheless,
414 the r^2 values were surprisingly low, at 0.52 and 0.46, respectively. In other words, in our Study
415 Cohort, only about half of the variation in one widely used online 10-year ASCVD risk estimate
416 can be statistically attributed to variation in the other. Moreover, the y-intercepts were 6.9% and
417 7.7%, which are substantial compared with the cutoffs of Arnett et al.[25] and indicate generally
418 higher 10-year ASCVD risk estimates from the QRisk3 than from the ACC ASCVD Risk
419 Estimator Plus, particularly at the latter's lower end. Visual inspection of Figure 3A-C and
420 Supplementary Figure S2A demonstrates this point as well.
421 Figure 3D indicates clinically meaningful agreement (green) and discordance (red, white)
422 amongst the three systems for estimating the risk of a future ASCVD event for individual
423 patients in the LE-ASCVD Study Cohort. As described in the Methods, we compared the two
424 online calculators with the newly proposed categories of ASCVD event risk for LE patients from
425 Keyes et al. by using the key cutoff of 7.5% estimated 10-year ASCVD event risk from Arnett et
426 al.'s guidelines for the general population, because estimates ≥7.5% come with substantially
427 more aggressive recommendations for management compared with recommendations for
428 estimates <7.5%.[25] In Figure 3D, green indicates clinically meaningful agreement, defined here

429 as classification of an LE patient into the "High Risk" or "Very High Risk" categories of Keyes
430 et al., with estimates of 10-year ASCVD event risk ≥7.5% from both of the online calculators.
431 Red indicates clinically significant discordance between the two online calculators, meaning one
432 estimate of 10-year ASCVD event risk <7.5% but the other ≥7.5% for the same LE patient.
433 White indicates discordance between Keyes et al. versus both of the online risk estimators, i.e.,
434 these patients are at High or Very High Risk according to Keyes et al., yet both online
435 calculators gave estimates of 10-year ASCVD event risk <7.5%. By these definitions of
436 clinically meaningful agreement and discordance, the three systems for estimating the risk of a
437 future ASCVD event were in agreement for only 100 of the 254 LE patients (39.4%), i.e.,
438 discordance for almost two-thirds of the LE patients (154/254, 60.6%) that could affect their
439 clinical management. Supplementary Figure S2B shows similar findings for the 194 LE patients
440 without age scaling.
441
442 *Clinically documented ASCVD Events and actual 10-year ASCVD event rate in the LE-ASCVD*
443 *Study Cohort*
444 Because of discordances amongst the three systems for estimating ASCVD event *risk*
445 (Figure 3), we sought to determine the actual 10-year ASCVD event *rate* in our LE-ASCVD
446 Study Cohort. Figure 4 shows the Kaplan-Meier curve of event-free survival, with 95%
447 confidence intervals, since enrollment. For completeness, Supplementary Figure S3 shows the
448 cumulative incidence of all documented MAACE in our LE-ASCVD Study Cohort, including
449 the period before enrollment (indicated at time 0) and then all first MAACE after enrollment
450 (time >0). Table 2 gives a breakdown of the types of MAACE.

451 The rate of ASCVD events for patients in the first 10 years after enrollment into our LE-
452 ASCVD Study Cohort was calculated as one minus the event-free survival at the 10-year time
453 point of the Kaplan-Meier survival curve (Figure 4). Thus, the 10-year ASCVD event rate was
454 22.3% (95% CI 16.9%, 27.4%), which is above Arnett et al.'s highest cut-off of 20%,[25]
455 indicating a high-risk population.

456 This 10-year ASCVD event rate in our LE-ASCVD Study Cohort is even more striking,
457 given the preponderance of women and the patients' relative youth at enrollment (Table 1). For
458 comparison, the ACC ASCVD Risk Estimator Plus gives an estimate of 10-year ASCVD event
459 risk ≥20% for a 47-year-old woman if she has a combination of diabetes, current smoking,
460 treated hypertension, an HDLc of 40 mg/dl, and a non-HDLc ≥250 mg/dl if Caucasian and ≥160
461 mg/dl if African-American.

462 **Discussion**

463 Our results indicate that CLE patients are under-treated compared with the new
464 guidelines for conventional therapeutic targets to prevent ASCVD events[1] and, accordingly,
465 these patients experience a substantial burden of major adverse ASCVD events despite our
466 youngish, predominantly female LE-ASCVD Study Cohort. Moreover, current methods give
467 discordant estimates of the risk for future ASCVD events, possibly because the online risk
468 calculators were not designed specifically for CLE patients. Thus, for patients with cutaneous
469 LE, it is unclear how to accurately assess their future ASCVD event risk – except that it is high –
470 and this uncertainty may complicate clinical management. Management of ASCVD event risk
471 has become a major issue in LE because of therapeutic success: lupus patients are now much less
472 likely to die prematurely from lupus directly or from infections, and so they are living long
473 enough to develop clinically significant atherosclerotic cardiovascular disease.[1, 6]

474 Specific areas of current concern include under-management of LDLc, non-HDLc, and
475 presumably apoB levels to the new guidelines;[1] under- or non-administration of LDL-lowering
476 therapies in primary and even secondary prevention; management of hypertension to recently
477 revised blood-pressure goals;[17, 33] under-use of resources for smoking cessation; infrequent
478 monitoring of above-goal LDLc and HbA_{1c} levels; under-management of prediabetes; and, as
479 noted above, clinically meaningful discordances in estimates of the risk for future ASCVD
480 events and a strikingly high 10-year ASCVD event rate. Areas of current success include high
481 levels of linkage with a PCP; evidence of widespread awareness amongst PCPs and sub-
482 specialists of conventional therapeutic targets for management of ASCVD event risk; generally
483 well-managed diabetes mellitus; and low prevalence of hypertriglyceridemia in the LE-ASCVD
484 Study Cohort even in patients with obesity and/or GC use.

485 Our findings add to a growing literature emphasizing the gaps between typical or usual
486 real-world care versus ideal guideline-based care in the management of ASCVD event risk in
487 lupus patients and in non-autoimmune populations, even ones at high risk. Several studies have
488 looked at rates of cardiovascular events in CLE cohorts.[1, 11] To our knowledge, however, ours is
489 the first study to focus on the management of ASCVD event risk in CLE, although there is prior
490 literature in SLE.[1] In one published study, a large proportion of a cohort of 110 patients with
491 SLE had indications for statins for primary or secondary prevention, but only about half of those
492 were treated to guidelines.[16] In a recently reported cohort of 1532 SLE patients,[17] 639 had
493 hypertension defined by the new cutoffs of ≥130/≥80 mm Hg or on anti-hypertensive
494 medications, but approximately three-quarters of these hypertensive SLE patients (471/639,
495 73.7%) were under- or un-treated, nearly identical to our figure of 74.4% (198/266, Figure 2A).
496 Moreover, lupus patients with blood pressures in the newly defined range for stage 1
497 hypertension, meaning 130–139/80–89 mm Hg,[33] had more than twice the rate of atherosclerotic
498 cardiovascular events than did normotensive lupus patients during a decade or so of follow-up.[17,
499 43] In other SLE cohorts as well, persistent hypertension has been associated with a much higher
500 incidence of ASCVD events, compared with ASCVD event rates in normotensive SLE
501 patients.[44]
502 In non-autoimmune populations, treatment of therapeutic targets to manage ASCVD
503 event risk, particularly hypercholesterolemia[45-49] and hypertension,[50, 51] remains sub-optimal in
504 the USA and worldwide. Particularly striking are under-utilization of evidence-based LDL- and
505 blood pressure-lowering medications in patients with diabetes mellitus,[52, 53] even when those
506 patients are at extreme ASCVD event risk owing to the additional presence of clinically evident
507 atherosclerosis (secondary prevention) on top of their type 2 diabetes.[48]

508 Reasons for this widespread pattern of undertreatment might stem from prioritization of
509 immediate clinical problems over long-term care, difficulties for patients and providers in
510 sustaining long-term treatment for subclinical conditions, time needed to disseminate and
511 implement recent guidelines, access to care, the difficulties of polypharmacy, evidence-based
512 and non-evidence-based concerns from patients and providers over potential side-effects,[49, 54]
513 and lifestyle and medication adherence. Further research is needed so that rational strategies can
514 be developed to address under-management of ASCVD event risk. Amongst conventional
515 therapeutic targets in the management of ASCVD event risk, levels of LDLc, non-HDLc, and
516 apoB can be managed without great concern of a lower limit,[55, 56] in contrast to blood pressure or
517 plasma glucose levels. Conventional interventions to assist smoking cessation and to manage
518 prediabetes also come with few risks.
519 Notably, our results emphasize the need to clarify how to appropriately assess the risk of
520 future ASCVD events in CLE patients. We demonstrated discordance amongst the three systems
521 that we used: the new risk classifications from Keyes et al. specifically for lupus patients,[1] the
522 ACC ASCVD Risk Estimator Plus,[24, 25] and the QRisk3 calculator.[26-28] A similar discordance
523 between the Framingham Risk Score and QRisk3 was recently reported for SLE patients in one
524 study[57] but less so in another study with a far smaller cohort.[16] As a statistical matter,
525 multiplying the 10-year estimate from the ACC Risk Estimator Plus by 1.5, as has been
526 proposed,[1, 39] would not improve the r^2 value of the correlation with QRisk3. Recent reports
527 suggest that QRisk3 may be a better predictor for lupus patients than other estimators of future
528 ASCVD event risk.[58, 59] Additional clinical parameters that may enhance assessment of ASCVD
529 event risk in lupus patients may include plasma apoB measurements,[1, 60] one-time assessments
530 of plasma lipoprotein(a) levels, which are still largely genetically determined[1], and arterial

531 imaging to detect subclinical plaque by femoral or carotid ultrasonography, coronary CT
532 angiography, and in older patients coronary artery calcium scores.[1]
533
534 *Study Limitations and Strengths*
535 Study limitations include the retrospective design, from a single medical center. In our
536 database, like many others, there are possible inaccuracies in smoking status because assays of
537 cotinine, a recognized marker of nicotine use, are not part of routine care. Lifestyle modifications
538 or medications discussed at a clinic visit but not entered into the charts could indicate a different
539 level of management. In addition, the standard of care for diabetes testing includes assays in
540 addition to HbA_{1c}, such as fasting glucose levels, oral glucose tolerance tests (OGTT), and
541 random plasma glucose levels, which may also be used to diagnose and assess prediabetes and
542 diabetes.[34] As noted in Figure 2C, many patients in our LE-ASCVD Study Cohort had no
543 available HbA_{1c} values, which affects our statistics on prevalence of prediabetes and diabetes and
544 their management.
545 Study strengths include a well-characterized longitudinal Cohort followed for over 14
546 years, with key parameters available in the electronic charts. The study assessed all available
547 conventional therapeutic targets in managing ASCVD event risk, which has not been previously
548 done in a comprehensive manner in CLE patients. Moreover, our results identified specific, key
549 issues in clinical management and decision-making. Based on our findings, efforts are now
550 underway to improve ASCVD event risk estimation and guideline implementation in lupus
551 patients.
552
553
554
555

556 *Contributions: MZ, VPW, and KJW, were involved in the conceptualizing the project, writing the*
557 *manuscript, and editing the manuscript. MZ was responsible for data collection, and MZ and*
558 *KJW were responsible for data verification. MZ, RF, and KJW were responsible for data*
559 *analysis.*

560 *Funding: Support by the Lupus Foundation of America was given for this study as part of the*
561 *2021 Gina M. Finzi Student Fellowship (to MZ). The work was also supported by the National*
562 *Institutes of Health-USA (NIH-USA) grants K24-AR02207 and R01AR071653 (to VPW), the*
563 *United States Department of Veterans Affairs (Veterans Health Administration, Office of*
564 *Research and Development and Biomedical Laboratory Research and Development, to VPW),*
565 *and the Ruth and Yonatan Ben-Avraham Fund (to KJW).*

566 *Competing interests: All authors declare no support from any organization for the submitted*
567 *work; no financial relationships with any organizations that might have an interest in the*
568 *submitted work in the previous three years; no other relationships or activities that could appear*
569 *to have influenced the submitted work. KJW discloses an ownership interest in Hygieia, Inc., a*
570 *company that provides insulin management services.*

571 *Data sharing: De-identified patient-level data, the full dataset, and statistical code are available*
572 *from the first author (MZ, megan.zhao@pennmedicine.upenn.edu). Participant consent for data*
573 *sharing was not obtained but the presented data are anonymized and risk of identification is low.*

574 *Ethics: This study was approved by the University of Pennsylvania Institutional Review Board;*
575 *IRB PROTOCOL#: 849182*

576 *Transparency Declaration: This manuscript is an honest, accurate, and transparent account of*
577 *the study being reported. There are no important aspects of the study have been omitted and*
578 *discrepancies have been explained. There are no competing interests.*

579 **References**

580 1. Keyes, E., et al., *Assessment and management of the heightened risk for atherosclerotic*
581 *cardiovascular events in patients with lupus erythematosus or dermatomyositis*. Int J
582 Womens Dermatol, 2021. **7**(5Part A): 560-575.
583 2. Akarsu, S., et al., *High prevalence of metabolic syndrome in patients with discoid lupus*
584 *erythematosus: a cross-sectional, case-control study*. J Immunol Res, 2017. **2017**:
585 3972706.
586 3. Miot, H.A., L.D. Bartoli Miot, and G.R. Haddad, *Association between discoid lupus*
587 *erythematosus and cigarette smoking*. Dermatology, 2005. **211**(2): 118-22.
588 4. Bockle, B.C. and N.T. Sepp, *Smoking is highly associated with discoid lupus*
589 *erythematosus and lupus erythematosus tumidus: analysis of 405 patients*. Lupus, 2015.
590 **24**(7): 669-74.
591 5. Guo, L.N. and V.E. Nambudiri, *Cutaneous lupus erythematosus and cardiovascular*
592 *disease: current knowledge and insights into pathogenesis*. Clin Rheumatol, 2021. **40**(2):
593 491-499.

6. Urowitz, M.B., et al., *The bimodal mortality pattern of systemic lupus erythematosus*. Am J Med, 1976. **60**(2): 221-5.
7. Roman, M.J., et al., *Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus*. N Engl J Med, 2003. **349**(25): 2399-406.
8. Asanuma, Y., et al., *Premature coronary-artery atherosclerosis in systemic lupus erythematosus*. N Engl J Med, 2003. **349**(25): 2407-15.
9. Carlucci, P.M., et al., *Neutrophil subsets and their gene signature associate with vascular inflammation and coronary atherosclerosis in lupus*. JCI Insight, 2018. **3**(8).
10. Salmon, J.E. and M.J. Roman, *Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus*. Am J Med, 2008. **121**(10 Suppl 1): S3-8.
11. Shams-Eldin, A.N., et al., *Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study*. Clin Rheumatol, 2022. **41**(11): 3525-3536.
12. Williams, K.J. and I. Tabas, *The response-to-retention hypothesis of early atherogenesis*. Arterioscler Thromb Vasc Biol, 1995. **15**(5): 551-61.
13. Borén, J. and K.J. Williams, *The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity*. Curr Opin Lipidol, 2016. **27**(5): 473-83.
14. Elliott, J.R., S. Manzi, and D. Edmundowicz, *The role of preventive cardiology in systemic lupus erythematosus*. Curr Rheumatol Rep, 2007. **9**(2): 125-30.
15. Munguia-Realpozo, P., et al., *Systemic lupus erythematosus and hypertension*. Autoimmun Rev, 2019. **18**(10): 102371.
16. Masson, W., et al., *Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies*. Clin Rheumatol, 2020. **39**(2): 455-462.
17. Tselios, K., et al., *Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus*. Ann Rheum Dis, 2020. **79**(5): 612-617.
18. Moghadam-Kia, S., et al., *Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients*. Arch Dermatol, 2009. **145**(3): 255-60.
19. Chang, A.Y., et al., *Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis*. Arch Dermatol, 2011. **147**(11): 1261-7.
20. Piette, E.W., et al., *Impact of smoking in cutaneous lupus erythematosus*. Arch Dermatol, 2012. **148**(3): 317-22.
21. Wieczorek, I.T., et al., *Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus*. JAMA Dermatol, 2014. **150**(3): 291-6.
22. Keyes, E., et al., *Comparative responsiveness of cutaneous lupus erythematosus patients to methotrexate and mycophenolate mofetil: A cohort study*. J Am Acad Dermatol, 2021. **98**(2): 447-448.
23. Zeidi, M., et al., *Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials*. Lupus, 2022. **31**(4): 472-481.
24. *American College of Cardiology. https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#!/calculate/estimate/*

25. Arnett, D.K., et al., *2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines*. Circulation, 2019. **140**(11): e596-e646.
26. Hippisley-Cox, J., C. Coupland, and P. Brindle, *Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study*. BMJ, 2017. **357**: j2099.
27. Edwards, N., et al., *QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus*. Lupus Sci Med, 2018. **5**(1): e000272.
28. QRISK3. https://qrisk.org/three/
29. The Global BMI Mortality Collaboration, *Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents*. Lancet, 2016. **388**(10046): 776-86.
30. Sniderman, A.D., *How, when, and why to use apolipoprotein B in clinical practice*. Am J Cardiol, 2002. **90**(8A): 48i-54i.
31. Wu, M.F., et al., *Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives*. Cardiovasc Drugs Ther, 2019. **33**(6): 739-748.
32. Page, M.M. and G.F. Watts, *Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology*. Curr Opin Cardiol, 2021. **36**(3): 272-280.
33. Whelton, P.K., et al., *2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines*. Hypertension, 2018. **71**(6): e13-e115.
34. American Diabetes Association, *2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2021*. Diabetes Care, 2021. **44**(Suppl 1): S15-S33.
35. Knowler, W.C., et al., *Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin*. N Engl J Med, 2002. **346**(6): 393-403.
36. Nathan, D.M. et al, *The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview*. Diabetes Care, 2014. **37**(1): 9-16.
37. Diabetes Prevention Program Research Group, *Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study*. Diabetes Care, 2019. **42**(4): 601-608.
38. Goldberg, R.B., et al., *Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study*. Circulation, 2022. **145**(22): 1632-1641.
39. Urowitz, M.B., et al., *Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus*. J Rheumatol, 2016. **43**(5): 875-9.
40. Kaplan, E.L., and P. Meier, *Nonparametric estimation from incomplete observations*. J Am Stat Assoc, 1958. **53.282**: 457-481.
41. Rich, J.T., et al., *A practical guide to understanding Kaplan-Meier curves*. Otolaryngol Head Neck Surg, 2010. **143**(3): 331-6.

42. Hesselvig, J.H., et al., *Increased risk of depression in patients with cutaneous lupus erythematosus and systemic lupus erythematosus: a Danish nationwide cohort study*. Br J Dermatol, 2018. **179**(5): 1095-1101.
43. Ming Wang, T.K., et al., *Cardiovascular manifestations, imaging, and outcomes in systemic lupus erythematosus: an eight-year single center experience in the United States*. Angiology, 2022. **73**(9): 877-886.
44. Kiani, A.N., et al., *Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus*. Rheumatology (Oxford), 2011. **50**(11): 2071-9.
45. Kuklina, E.V., P.W. Yoon, and N.L. Keenan, *Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006*. JAMA, 2009. **302**(19): 2104-10.
46. Carroll, M.D., et al., *Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2011-2012*. NCHS Data Brief, 2013(132): 1-8.
47. Mercado, C., et al., *Prevalence of cholesterol treatment eligibility and medication use among adults--United States, 2005-2012*. MMWR Morb Mortal Wkly Rep, 2015. **64**(47): 1305-11.
48. Nelson, A.J., et al., *Use of lipid-, blood pressure-, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease*. JAMA Netw Open, 2022. **5**(2): e2148030.
49. Stone, N.J., *Treating Severe Hypercholesterolemia-If Not Now, When?* JAMA Cardiol, 2022. **7**(2): 128-129.
50. Yoon, S.S., et al., *Trends in blood pressure among adults with hypertension: United States, 2003 to 2012*. Hypertension, 2015. **65**(1): 54-61.
51. Ciemins, E.L., et al., *Application of a Tool to Identify Undiagnosed Hypertension - United States, 2016*. MMWR Morb Mortal Wkly Rep, 2018. **67**(29): 798-802.
52. Kazemian, P., et al., *Evaluation of the Cascade of Diabetes Care in the United States, 2005-2016*. JAMA Intern Med, 2019. **179**(10): 1376-1385.
53. Fang, M., et al., *Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018*. N Engl J Med, 2021. **384**(23): 2219-2228.
54. Wood, F.A., et al., *N-of-1 Trial of a statin, placebo, or no treatment to assess side effects*. N Engl J Med, 2020. **383**(22): 2182-2184.
55. Mach, F., et al., *2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk*. Eur Heart J, 2020. **41**(1): 111-188.
56. Ference, B.A., *Interpreting the clinical implications of drug-target Mendelian randomization studies*. J Am Coll Cardiol, 2022. **80**(7): 663-665.
57. Sivakumaran, J., et al., *Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus*. Lupus Sci Med, 2021. **8**(1).
58. Zhu, L., et al., *Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus*. Lupus Sci Med, 2022. **9**(1).
59. Quevedo-Abeledo, J.C., et al., *QRISK3 relation to carotid plaque is higer than that of score in patients with systemic lupus erythematosus*. Rheumatology (Oxford), 2022. **61**(4): 1408-1416.
60. Sniderman, A.D., et al., *Apolipoprotein B particles and cardiovascular disease: a narrative review*. JAMA Cardiol, 2019. **4**(12): 1287-1295.

729 **Tables and Figures**
730
731 **Table 1.** Demographics and other characteristics of the LE-ASCVD Study Cohort.
732 Here and elsewhere, categorical parameters are given as n (%). Continuous variables are given as
733 mean±SD, if normally distributed, or as median (interquartile range, IQR), if non-normally
734 distributed.

Category	Parameter	Value	n in LE-ASCVD Study Cohort or subgroup
Demographics			
	Female	305 (82.4%)	370 (entire LE-ASCVD Study Cohort)
	White	190 (51.4%)	370
	Black	141 (38.1%)	370
	Asian	15 (4.1%)	370
	Hispanic	17 (4.6%)	370
Clinical course and care in the Cohort			
	Age at enrollment into the Cohort	47.1±14.9 years	370
	Age as of 2021	54.8±15.9 years	370
	Length of time since enrollment into the Cohort	7.7±4.5 years	370
	Extreme Risk for future ASCVD events*	82 (22.2%)	370
	CLE patients with concurrent SLE	190 (51.4%)	370
	History of lupus nephritis	42 (11.4%)	370
	History of CKD stage 3 or 4‡	37 (10.0%)	370
	Hypertension§	266 (71.9%)	370
	Former Smokers	109 (29.5%)	370
	Current Smokers	63 (17.0%)	370
	Most recent BMI	28.4±7.1 kg/m^2	346 (subgroup with at least one set of simultaneous height and weight measurements)
	Obese (BMI ≥30.0 kg/m^2)	116 (33.5%)	346
	Prediabetes	67 (18.1%)	370

	Diabetes mellitus	39 (10.5%)	370
Provider Data			
	Patients with a listed PCP in the chart	336 (90.8%)	370
	Patients with documented PCP visit in the chart	279 (75.4%)	370

735 BMI, body mass index; PCP, primary care provider.
736 *Extreme ASCVD event risk was defined by Keyes et al. 2021 as "Patients with LE … and
737 clinically evident ASCVD", i.e., secondary prevention in the context of LE.[1]
738 ‡An additional five (1.4%) patients in the LE-ASCVD Study Cohort were in CKD stage 5,
739 meaning an eGFR below 15 ml/min/1.73m^2.
740 §Hypertension was defined following Whelton et al. 2018 as a systolic BP ≥130 mm Hg, a
741 diastolic BP ≥80 mm Hg, and/or on an anti-hypertensive medication,[33] here based on averaged
742 blood pressure readings from the most recent year of follow-up, plus the list of active
743 prescriptions in the electronic charts. 341 patients (92.3% of the LE-ASCVD Cohort) had two or
744 more readings in their electronic charts in this period; 28 patients (7.6%) had only one reading;
745 and 1 patient had no available blood pressure value in the most recent year.
746
747
748

749
750 **Table 2.** Types, numbers, and timing of major adverse atherosclerotic cardiovascular events
751 (MAACE) documented in the LE-ASCVD Study Cohort.
752

Type of MAACE	Number affected (% of the 370 patients in the LE-ASCVD Study Cohort)*	Time from enrollment to event in years, given as median (IQR); and number of events (n)‡
Atherosclerotic myocardial infarction (MI)	14 (3.8%)	6.5 (4-11); n=12
Newly diagnosed ischemic heart disease other than MI	31 (8.4%)	8.0 (5-13); n=25
Atherosclerotic (non-embolic) ischemic stroke or transient cerebrovascular ischemic attack	15 (4.1%)	11.0 (7-14); n=10
Newly diagnosed symptomatic peripheral vascular disease (PVD)	3 (0.8%)	5.0; n=3
Hospitalization for chest pain, shortness of breath, or palpitations with suspicion of ischemic origin	29 (7.8%)	7.0 (5-8); n=28
Any MAACE	82 (22.2%)	7.0 (5-11); n=65

753 *Any patient who experienced two or more MAACE before and since enrollment was counted
754 only once in any given row but was counted in two or more rows if the types of MAACE
755 differed. Thus, the sum of the numbers of patients affected by each specific type of MAACE (92
756 total, 78 since enrollment) is slightly larger than the number of patients affected by any MAACE
757 (82 total, 65 since enrollment).
758 ‡Time and n in this column exclude the 17 events that were documented in lupus patients before
759 their enrollment in the LE-ASCVD Study Cohort. IQR ranges are given for each type of
760 MAACE only if n ≥6.
761

Figure 1. Assessment and management of plasma low-density lipoprotein cholesterol (LDLc) concentrations in the LE-ASCVD Study Cohort. Panel A: Classification of Study Cohort patients into the four categories of ASCVD event risk defined by the newly proposed guidelines of Keyes et al. for lupus patients.[1] Also indicated are numbers of patients with LDLc levels above (red) or within (green) the newly proposed goals for each risk category. Patients without an available LDLc value are indicated in blue. Panel B: Absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic charts of patients classified into each of the four newly proposed categories of ASCVD event risk for lupus patients and whose most recent plasma LDLc levels were above the newly proposed goals; these are the patients indicated in red in panel 1A. Panel C: Estimated risk of an ASCVD event in the next 10 years ("10-year ASCVD event risk") by the online ACC Risk Estimator Plus and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. Patients are grouped according to the cut-offs for estimated 10-year ASCVD event risk from the ACC/AHA Guideline on primary prevention (0.0-4.9%, 5.0-7.4%, &c.).[25] As noted in the Methods, patients below age 40 years without clinically evident ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus (n=47/370) were scaled up to 40, and patients above age 79 years without clinically evident ASCVD (n=13/370) were scaled down to 79. Data are presented with these additional patients included (here) or presented separately in their own columns (Supplementary Figure S1C). Also shown here are data for patients with clinically evident ASCVD (meaning secondary prevention, for which the ACC ASCVD Risk Estimator Plus does not apply), as well as data for patients with no clinically evident ASCVD but insufficient information in the electronic chart for the ACC Risk Estimator (rightmost column). Panel D: Most recent LDLc values and absence (red) or presence (green) of an active prescription for an LDL-lowering medication in the electronic chart. The rightmost column represents patients with no LDLc value in the electronic chart. At the top of each column in panels A-D is indicated the total number of patients represented by that column. Numbers of patients represented by each tinted portion of each column are also given.


A
n=52
n=236
n=82
n=0
250
200
150
100
50
0
Number of Patients
11
11
30
179
22
35
62
12
8
0
High Risk
Very High Risk
Extreme Risk
Recent Recurrent ASCVD Events
Above Recommended LDLc Goal
No LDLc Value Available
Within Recommended LDLc Goal


B
n=11
n=179
n=62
n=0
Number of Patients
200
180
160
140
120
100
80
60
40
20
0
126
53
25
37
10
1
0
High Risk With LDLc Above Goal
Very High Risk With LDLc Above Goal
Extreme Risk With LDLc Above Goal
Recent Recurrent ASCVD Events with LDLc Above Goal
Not on LDL-Lowering medication
On LDL-Lowering medication


C
n=132
n=21
n=73
n=28
n=82
n=34
Number of Patients
140
120
100
80
60
40
20
0
115
17
14
7
43
30
12
16
34
48
33
1
Estimated 10-Year ASCVD Event Risk by ACC Risk Estimator Plus (%)
0.0 - 4.9
5.0 - 7.4
7.5 - 19.9
≥20.0
Clinically Evident ASCVD
Insufficient Data for ACC Risk Estimator
Not On LDL-Lowering Medication
On LDL-Lowering Medication


D
n=57
n=119
n=93
n=41
n=9
n=6
n=45
Number of Patients
140
120
100
80
60
40
20
0
32
25
83
36
62
31
26
15
7
2
2
4
39
6
LDLc (mg/dL) <70
70-99
100-129
130-159
160-189
≥190
No LDLc Value Available
Patients Not on LDL-Lowering Medication
Patients on LDL-Lowering Medication

829 **Figure 2.** Assessment and management of several exacerbators and an additional causative agent
830 of ASCVD event risk in the LE-ASCVD Study Cohort. Panel A: Prevalence and management of
831 hypertension. Under-treated or untreated hypertension is defined by a blood pressure (BP)
832 ≥130/80 mm Hg, meaning a systolic BP ≥130 and/or a diastolic BP ≥80. Red indicates patients
833 with no record of an active prescription for an anti-hypertensive medication in the electronic
834 chart; green indicates patients on at least one anti-hypertensive medication. Panel B: Prevalence
835 and management of tobacco smoking. Red indicates patients with no chart documentation of
836 either smoking cessation counseling or a referral to a smoking cessation clinic; green indicates
837 patients with a record of one or both of these interventions. Data from never-smokers are also
838 shown (blue). Panel C: Assessment, or not (red), of glycated hemoglobin (HbA_{1c}) values for
839 patients stratified by obesity and/or glucocorticoid (GC) use, two common factors in lupus
840 patients that impair glycemic control. Diabetes is defined as chart-diagnosed or the most recent
841 HbA_{1c} was ≥6.5%; yellow indicates diabetes and at least one HbA_{1c} value on the chart. Five
842 patients had a diagnosis of diabetes on their charts but no available HbA_{1c} value; these patients
843 are included within the red portions of the columns here. Prediabetes (blue) is defined as chart-
844 diagnosed or the most recent HbA_{1c} was 5.7-6.4%, without a diagnosis of overt diabetes on the
845 chart. Green indicates patients with at least one HbA_{1c} value on the chart and no indication of
846 either prediabetes or diabetes. Panel D: Management of prediabetes and diabetes in the LE-
847 ASCVD Study Cohort. For prediabetes, well-managed (green) is defined here as documentation
848 in the chart of lifestyle counseling and/or an active prescription for metformin. For diabetes,
849 well-managed (green) is defined here as the most recent HbA_{1c} ≤7%. Red indicates not well-
850 managed by these definitions. Yellow in this panel indicates a diagnosis of diabetes but no
851 available HbA_{1c} value on the chart. Panel E: Assessment, or not (red), of plasma triglyceride
852 (TG) concentrations for patients stratified by obesity and/or GC use, two common factors in
853 lupus patients that can elevate plasma TGs. Most recent plasma TG values are classified as very
854 high (≥500 mg/dl, yellow), high (200-499 mg/dl, blue), or <200 mg/dl (green).
855



856
857


B
n=197
n=109
n=63
n=1
Number of Patients
250
200
150
100
50
0
197
92
17
51
12
1
Never Smoker
Former Smoker
Current Smoker
No Smoking Status Available
No Documented Smoking Cessation Counseling or Referral to Smoking Cessation Clinic
Documented Smoking Cessation Counseling or Referral to Smoking Cessation Clinic
Never Smoker

858
859


C
n=154
n=100
n=72
n=44
Number of Patients
180
160
140
120
100
80
60
40
20
0
72
8
28
46
51
5
12
32
22
12
22
16
17
9
5
13
Not obese and not on GC
Not obese but on GC
Obese and not on GC
Obese and on GC
Not Checked
Checked (Diabetes)
Checked (Prediabetes)
Checked (No Diabetes or Prediabetes)

860


D
n=107
n=67
n=39
120
100
80
60
40
20
0
Number of Patients
107
33
34
4
5
30
No Diabetes or Prediabetes
Prediabetes
Diabetes
Not Well-Managed
No available HbA1c value
Well-Managed


E
n=154
n=100
n=72
n=44
180
160
140
120
100
80
60
40
20
0
Number of Patients
21
0
7
126
10
2
5
83
4
0
5
63
4
0
3
37
Not obese and not on GC
Not obese but on GC
Obese and not on GC
Obese and on GC
TG Not Checked
Checked (TG ≥500 mg/dL)
Checked (TG 200-499 mg/dL)
Checked (TG <200 mg/dL)

Figure 3. Three systems to estimate the risk of a future ASCVD event for individual patients within the LE-ASCVD Study Cohort. The three system were the ASCVD event risk categories defined by Keyes et al. for LE patients (reference[1] and Fig 1A); and numerical estimates of the risk of an ASCVD event in the next 10 years ("10-year ASCVD event risk") generated by two widely used online calculators: QRisk3 (y-axis) versus the American College of Cardiology (ACC) ASCVD Risk Estimator Plus (x-axis). Data are shown for the subset of patients in the Study Cohort for whom both online calculators could be used, meaning no clinically evident ASCVD (primary prevention) and sufficient data in the electronic charts to allow use of these online tools. Data are presented with (here, n=254) and without (Supplementary Figure S2, n=194) age scaling for the ASCVD Risk Estimator Plus. Each dot represents an individual patient. Blue dots indicate patients classified at "High Risk" (n=41/254), and yellow dots indicate patients classified at "Very High Risk" (n=213/254) according to Keyes et al. The horizontal and vertical dashed gray lines indicate the key cut-off of 7.5% estimated 10-year ASCVD event risk from Arnett et al. 2019,[25] for each of the two calculators. P-values were calculated with linear regression. Panel A: Three estimates of ASCVD event risk for each of the 254 eligible LE patients. Pearson's linear correlation was used to test the statistical relationship between the two numerical estimates of 10-year ASCVD event risk, and the calculated regression line is indicated in dashed red with key parameters given on the right. Panel B: Estimates of 10-year ASCVD event risk for LE patients classified into the "High Risk" category of Keyes et al. The panel has been expanded for ease of viewing the data. Panel C: Estimates of 10-year ASCVD event risk for LE patients classified into the "Very High Risk" category of Keyes et al. The panel allows an unobstructed view of the data for these Very High Risk patients. Panel D: Clinically meaningful agreement (green) and discordance (red, white) amongst the three systems for estimating the risk of a future ASCVD event for individual patients in the LE-ASCVD Study Cohort. The two pie charts tabulate patients from Fig. 3B ("High Risk" as defined by Keyes et al., n=41) and Fig. 3C ("Very High Risk" as defined by Keyes et al., n=213). Green indicates clinically meaningful agreement, defined here as classification of an LE patient into the "High Risk" or "Very High Risk" categories of Keyes et al., with estimates of 10-year ASCVD event risk ≥7.5% from both of the online calculators. Red indicates clinically significant discordance between the two online calculators, meaning one estimate of 10-year ASCVD event risk <7.5% but the other ≥7.5% for the same LE patient. White indicates discordance between Keyes et al. versus both of the online risk estimators, i.e., these patients are at High or Very High Risk according to Keyes et al., yet both online calculators gave estimates of 10-year ASCVD event risk <7.5%. Numbers of patients represented by each portion of each pie chart are also given.


A
Estimated 10-Year ASCVD Event Risk by QRisk3 (%)
Estimated 10-Year ASCVD Event Risk by ACC Risk Estimator Plus (%)
0
10
20
30
40
50
60
70
80
r2=0.515, n=254
p=1.77659×10-41
y=0.9228x+6.8558


B
Estimated 10-Year ASCVD Event Risk by QRisk3 (%)
30
25
20
15
10
5
0
0
5
10
15
20
Estimated 10-Year ASCVD Event Risk
by ACC Risk Estimator Plus (%)


C
Estimated 10-Year ASCVD Event Risk by QRisk3 (%)
0
10
20
30
40
50
60
70
80
0
10
20
30
40
50
60
Estimated 10-Year ASCVD Event Risk
by ACC Risk Estimator Plus (%)


D
High Risk (n=41)
QRisk3 ≥7.5%, ACC <7.5%
QRisk3 ≥7.5%, ACC ≥7.5%
5
6
30
QRisk3 <7.5%, ACC <7.5%
Very High Risk (n=213)
QRisk3 ≥7.5%, ACC <7.5%
QRisk3 ≥7.5%, ACC ≥7.5%
54
94
64
QRisk3 <7.5%, ACC <7.5%
1
QRisk3 <7.5%, ACC ≥7.5%

Figure 4. Kaplan-Meier curve of event-free survival since enrollment in the LE-ASCVD Study Cohort. An event was defined as a patient's first documented major adverse atherosclerotic cardiovascular event (MAACE) after enrollment. Displayed are median event-free survival rates over time (solid black stepped curve) with 95% confidence intervals (dashed curves). Following our definition, the 17 MAACE that were documented before enrollment are not shown on this graph. All patients in the LE-ASCVD Study Cohort were included in this survival curve. The actual documented 10-year ASCVD event rate in this Cohort was calculated as one minus the event-free survival rate of 0.777 (95% CI 0.726, 0.831) at the 10-year time point, which is highlighted by the thin vertical gray line.



975 **Supplementary Table and Figures**
976
977 **Supplementary Table S1.** Additional characteristics of the LE-ASCVD Study Cohort.
978 Categorical parameters are given as n (%). Continuous variables are given as mean±SD, if
979 normally distributed, or as median (interquartile range, IQR), if non-normally distributed.

Category	Parameter	Value	n in LE-ASCVD Study Cohort or subgroup
Additional clinical characteristics			
	Time since diagnosis of cutaneous LE	13.0 years (IQR 8.25-21.0)	370 (entire LE-ASCVD Study Cohort)
	Time since diagnosis of cutaneous LE	15.0 years (IQR 10.0-25.0)	190 (subgroup of CLE patients who have concurrent SLE)
	Time since diagnosis of systemic LE	13.0 years (IQR 8.00-23.8)	190 (same subgroup as above)
	Underweight (BMI <18.5 kg/m^2, common definition)	13 (3.8%)	346 (subgroup with at least one set of simultaneous height and weight measurements)
	Underweight (BMI <20.0 kg/m^2 [29])	21 (6.1%%)	346
	Normal weight (BMI 18.5 to 24.9 kg/m^2, common definition)	112 (32.4%)	346
	Normal weight (BMI 20.0-24.9 kg/m^2 [29])	104 (30.1%)	346
	Overweight (BMI 25.0 to 29.9 kg/m^2)	105 (30.3%)	346
	Diagnosis of depression in the electronic chart	139 (37.6%)	370
Additional data regarding providers			
	Time since last visit with PCP	10 months (IQR 4.0-31)	279 (subgroup with at least one PCP visit documented in the chart)

	Number of physician providers, excluding trainees	5.8±2.8 (mean±SD)	370
	Patients who have a recorded visit with a rheumatologist	203 (54.9%)	370
	Patients who have a recorded visit with a cardiologist	151 (40.8%)	370
	Patients who have a recorded visit with a nephrologist	57 (15.4%)	370
	Patients who have a recorded visit with an endocrinologist	33 (8.0%)	370
Assessments of plasma lipids/lipoproteins			
	Lipids/lipoproteins checked at least once	325 (87.8%)	370
	Time since the most recently documented lipid/lipoprotein assay	35 months (IQR 14-83)	325 (subgroup with at least one lipid/lipoprotein result in the chart)
	PCP checked the most recent lipids/lipoproteins	204 (62.8%)	325
	Non-PCPs checked the most recent lipids/lipoproteins	121 (37.2%)	325
	• Rheumatology	35 (28.9%)	121 (subgroup for whom non-PCPs checked the most recent lipids/lipoproteins)
	• Cardiology	15 (12.4%)	121
	• Nephrology	15 (12.4%)	121
	• Endocrinology	3 (2.5%)	121
	• Emergency	19 (15.7%)	121
	• Dermatology	15 (12.4%)	121
	• Other	19 (15.7%)	121
	Time elapsed since above-goal LDLc value	47 months (IQR 24-97)	252 (subgroup of patients whose most recently documented LDLc

			value in the chart was above the newly recommended goals, i.e., red in Figure 1A)
Assessments of levels of glycated hemoglobin (HbA_{1c})			
	HbA_{1c} checked at least once	208 (56.2%)	370 (entire LE-ASCVD Study Cohort)
	Time elapsed since the most recently documented HbA_{1c} assay	36 months (IQR 11-68)	208 (subgroup with at least one HbA_{1c} value in the chart)
	PCP checked the most recent HbA_{1c}	132 (65.3%)	202
	Non-PCPs checked the most recent HbA_{1c}	70 (34.7%)	202
	• Rheumatology	18 (25.7%)	70 (subgroup for whom non-PCPs checked the most recent HbA_{1c})
	• Cardiology	14 (20.0%)	70
	• Nephrology	2 (2.9%)	70
	• Endocrinology	3 (4.3%)	70
	• Emergency	12 (17.1%)	70
	• Dermatology	9 (12.9%)	70
	• Other	12 (17.1%)	70
	Time elapsed since abnormal HbA_{1c} value	48 months (IQR 24-80)	89 (subgroup of patients whose most recently documented HbA_{1c} value in the chart was abnormal, meaning ≥5.7%)

980
981

982 **Supplementary Figure S1.** Assessment and management of plasma non-high-density
983 lipoprotein cholesterol (non-HDLc) concentrations in the LE-ASCVD Study Cohort. Panel A:
984 Classification of Study Cohort patients into the four categories of ASCVD event risk defined by
985 the newly proposed guidelines of Keyes et al. for lupus patients.[1] Also indicated are numbers of
986 patients with non-HDLc levels above (red) or within (green) the newly proposed goals for each
987 risk category. Patients without an available non-HDLc value (or no simultaneous total
988 cholesterol and HDLc) are indicated in blue. Panel B: Absence (red) or presence (green) of an
989 active prescription for an LDL-lowering medication in the electronic charts of patients classified
990 into each of the four newly proposed categories of ASCVD event risk for lupus patients and
991 whose most recent plasma non-HDLc levels were above the newly proposed goals; these are the
992 patients indicated in red in panel S1A. Panel C: Estimated risk of an ASCVD event in the next
993 10 years ("10-year ASCVD event risk") by the online ACC Risk Estimator Plus and absence
994 (red) or presence (green) of an active prescription for an LDL-lowering medication in the
995 electronic chart. Patients are grouped according to the cut-offs for estimated 10-year ASCVD
996 event risk from the ACC/AHA Guideline on primary prevention (0.0-4.9%, 5.0-7.4%, &c).[25] As
997 noted in the Methods and in Figure 1, patients below age 40 years without clinically evident
998 ASCVD for whom we had sufficient data for the ACC ASCVD Risk Estimator Plus (n=47/370)
999 were scaled up to 40, and patients above age 79 years without clinically evident ASCVD
1000 (n=13/370) were scaled down to 79. Data are presented with these additional patients included
1001 (Figure 1C) or presented separately (here). Also shown here are data for patients with clinically
1002 evident ASCVD (secondary prevention, for which the ACC ASCVD Risk Estimator Plus does
1003 not apply), as well as data for patients with no clinically evident ASCVD but insufficient
1004 information in the electronic chart for the ACC Risk Estimator (rightmost column). Panel D:
1005 Most recent non-HDLc values and absence (red) or presence (green) of an active prescription for
1006 an LDL-lowering medication. The rightmost column represents patients with no non-HDLc
1007 value (or no simultaneous total cholesterol and HDLc) in the electronic chart. At the top of each
1008 column in panels A-D is indicated the total number of patients represented by that column.
1009 Numbers of patients represented by each tinted portion of each column are also given.
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026


A
n=52
n=236
n=82
n=0
250
200
150
100
50
0
Number of Patients
7
11
34
157
22
57
59
12
11
0
High Risk
Very High Risk
Extreme Risk
Recent Recurrent ASCVD
Above Recommended non-HDLc Goal
No non-HDLc Value Available
Within Recommended non-HDLc Goal



1029
1030



1031
1032
1033


D
n=33
n=68
n=113
n=74
n=24
n=11
n=2
n=45
120
100
80
60
40
20
0
Number of Patients
15
18
42
26
80
33
52
22
15
9
7
4
1
1
39
6
Non-HDLc (mg/dL)
<80
80-99
100-129
130-159
160-189
190-219
≥220
No non-HDLc Value Available
Not On LDL-Lowering Medication
On LDL-Lowering Medication

1034
1035

1036 **Supplementary Figure S2.** Three systems to estimate the risk of a future ASCVD event for
1037 individual patients in the LE-ASCVD Study Cohort, as described in Figure 3. Data are shown
1038 for the subset of patients in the Study Cohort for whom both online calculators could be used,
1039 meaning no clinically evident ASCVD (primary prevention) and sufficient data in the electronic
1040 charts to allow use of these online tools. P-values were calculated with linear regression. Panel
1041 A: Presentation of data with (Figure 3A, n=254) and without (here, n=194) age scaling for the
1042 ACC ASCVD Risk Estimator Plus. Each dot represents an individual patient. Blue dots indicate
1043 patients classified at "High Risk" (n=31/194), and yellow dots indicate patients classified at
1044 "Very High Risk" (n=163/194) according to Keyes et al.[1] The horizontal and vertical dashed
1045 gray lines indicate the key cut-off of 7.5% estimated 10-year ASCVD event risk from Arnett et
1046 al. 2019,[25] for each of the two calculators. As in Fig. 3A, Pearson's linear correlation was used
1047 to test the statistical relationship between the two numerical estimates of 10-year ASCVD event
1048 risk, and the calculated regression line is indicated in dashed red with key parameters given on
1049 the right. Panel B: Clinically meaningful agreement (green) and discordance (red, white)
1050 amongst the three systems for estimating the risk of a future ASCVD event for individual
1051 patients in the LE-ASCVD Study Cohort; this panel is same as Figure 3D but does not include
1052 patients whose ages were scaled to allow use of the ACC ASCVD Risk Estimator Plus.
1053


A
Estimate of QRisk3 10-Year ASCVD Event Risk (%)
Estimated 10-Year ASCVD Event Risk
by ACC Risk Estimator Plus (%)
0
10
20
30
40
50
60
70
80
r2=0.4612, , n=194
p-value=1.3956×10-27
y = 0.8765 x + 7.6674


B
High Risk (n=31)
QRisk3 ≥7.5%, ACC <7.5%
QRisk3 ≥7.5%, ACC ≥7.5%
4
6
21
QRisk3 <7.5%, ACC <7.5%
Very High Risk (n=163)
QRisk3 ≥7.5%, ACC <7.5%
QRisk3 ≥7.5%, ACC ≥7.5%
44
79
39
QRisk3 <7.5%, ACC <7.5%
QRisk3 <7.5%, ACC ≥7.5%
1

1061 **Supplementary Figure S3.** Cumulative incidence of documented major adverse atherosclerotic
1062 cardiovascular events (MAACE) in the LE-ASCVD Study Cohort. The 17 events that were
1063 documented before enrollment in the LE-ASCVD Study Cohort occurred in 17 lupus patients
1064 and are indicated at time 0 (n=17/370, 4.59%). For all patients, the first MAACE after
1065 enrollment was counted for this curve (time >0) but no subsequent MAACE. After enrollment,
1066 the numbers of patients in the Cohort year by year are consistently higher than the numbers at
1067 risk in the Kaplan-Meier curve of event-free survival (Figure 4), because when a patient has a
1068 non-fatal event, he or she becomes censored from the K-M curve, but still remains in the Cohort.
1069



1070
1071
1072